Sugammadex versus neostigmine for antagonism of rocuronium-induced neuromuscular blockade in infants with biliary atresia undergoing kasai operation . A randomized control trial

Sugammadex versus neostigmine for antagonism of rocuronium-induced neuromuscular blockade in infants with biliary atresia undergoing kasai operation: A randomized control trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR201907522427588

Enrollment

Registered

2019-07-05

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Neostigmine

Sugammadex

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - infants aged below 3 months undergoing kasai operation. - American Society of Anesthesiologists physical status class I-II

Exclusion criteria

Exclusion criteria: - Co-existing known or suspected neuromuscular disease, renal impairment, medications known to affect neuromuscular transmission e.g. aminoglycoside antibiotics or magnesium sulphate, bleeding tendency, and intraoperative events e.g. (massive bleeding and hypothermia).

Design outcomes

Primary

Measure	Time frame
The time from the start of sugammadex or neostigmine administration to recovery of the train of four (TOF ratio to 0.9.)	—

Secondary

Measure	Time frame
- Duration of anaesthesia and surgery	—

Countries

Egypt

Contacts

Public ContactGASSER ELAZAB

g-elazb@l.ver.menofia.edu.eg01289663992

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026